Literature DB >> 17033447

Imatinib mesylate-induced acute hepatitis with autoimmune features.

Valérie Dhalluin-Venier1, Caroline Besson, Stéphanie Dimet, Anne Thirot-Bibault, Gilbert Tchernia, Catherine Buffet.   

Abstract

Autoimmune hepatitis is a disorder of unknown aetiology. Imatinib belongs to a new class of anticancer agents with high selectivity toward a specific molecular target. Its main indications are chronic myeloid leukaemia and gastrointestinal tumours. We report here, for the first time to our knowledge, imatinib mesylate-induced hepatitis with autoimmune features.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17033447     DOI： 10.1097/01.meg.0000243867.56454.13

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN： 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

2.  Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient.

Authors:  Maria Salvado; Victor Vargas; Marta Vidal; Macarena Simon-Talero; Jessica Camacho; Josep Gamez
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.

Authors:  Onder Tonyali; Ugur Coskun; Ramazan Yildiz; Tarkan Karakan; Umut Demirci; Nalan Akyurek; Mustafa Benekli; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2009-08-07       Impact factor: 3.064

Review 4.  Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.

Authors:  Stergios Boussios; George Pentheroudakis; Konstantinos Katsanos; Nicholas Pavlidis
Journal:  Ann Gastroenterol       Date:  2012

5.  A Case of Imatinib-Induced Hepatitis.

Authors:  Osman Bhatty; Mohammad Selim; Thamer Kassim; Lakshmi Chintalacheruvu; Manuel Urra; Sonia Shah; Joseph Haggerty; John Gross; Aravdeep Jhand; Gene Pershwitz; Jaya Gupta
Journal:  Cureus       Date:  2017-06-01

6.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.